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716ABSTRACT
Background. There is increasing interest in the development of vessel substitutes, and
many studies are currently focusing on the development of biodegradable scaffolds capable
of fostering vascular regeneration. We tested a new biocompatible and biodegradable
material with mechanical properties similar to those of blood vessels.
Methods. The material used comprises a mixture of a,b-poly(N-2-hydroxyethyl)-
D,L-aspartamide (PHEA) and polylactic acid (PLA), combined with polycaprolactone
(PCL) by means of electrospinning technique. Low-molecular-weight heparin was also
linked to the copolymer. A tubular PHEA-PLA/PCL sample was used to create an
arteriovenous ﬁstula in a pig model with the use of the external iliac vessels. The ﬂow
was assessed by means of Doppler ultrasound examination weekly, and 1 month after
the implantation we removed the scaffold for histopathologic evaluation.
Results. The implants showed a perfect leak-proof seal and adequate elastic tension to
blood pressure. About w3 weeks after the implantation, Doppler examination revealed
thrombosis of the graft, so we proceeded to its removal. Histologic examination showed
chronic inﬂammation, with the presence of foreign body cells and marked
neovascularization. The material had been largely absorbed, leaving some isolated spot
residues.
Conclusions. The biocompatibility of PHEA-PLA/PCL and its physical properties make
it suitable for the replacement of vessels. In the future, the possibility of functionalizing the
material with a variety of molecules, to modulate the inﬂammatory and coagulative
responses, will allow obtaining devices suitable for the replacement of native vessels.Funding: PRIN 2015: “Chirurgia rigenerativa nei difetti della
parete addominale e nel deﬁcit congenito o acquisito delle
vie escretrici urinarie, biliari e dei vasi sanguigni: mod-
ellamento e crescita cellulare su scaffold planare e su scaffold
tubulare. Studio sperimentale in vivo su modello suino”
(2015X5AH3Z).
*Address correspondence to Salvatore Buscemi, University of
Palermo, Via Del Vespro, 129, 90127 Palermo, Italy. E-mail:
buscemi.salvatore@gmail.comIN clinical practice, there is a strong need for alternativesto the use of autologous vascular grafts for vascular
reconstructive surgery (eg, coronary bypass, bypass of the
lower limbs, arteriovenous ﬁstulas) [1,2]. Currently, autol-
ogous vessels, especially the saphenous vein, are the most
widely used materials for the replacement of small arterial
vessels [1e3]. Immunologic compatibility is one of the
biggest advantages of using these patches; however, some-
times we cannot use human autologous as vascular sub-
stitutes and we have to resort to an alternate patch. The
biologic patches used are limited to some prostheses and are7
.org/10.1016/j.transproceed.2017.02.017
ª 2017 Elsevier Inc. All rights reserved.
230 Park Avenue, New York, NY 10169
Transplantation Proceedings, 49, 716e721 (2017)
PHEA-PLA/PCL SCAFFOLD FOR VASCULAR REGENERATION 717often represented by autologous pericardium, allogeneic or
xenogeneic (ﬁxed in glutaraldehyde). Unfortunately, these
patches have well known limitations: They are subject to
greater risk of infections and thrombosis, they tend to
calcify, and often they cause foreign body reactions and do
not guarantee an adequate growth potential [4e10].
Vascular grafts made from synthetic materials, such as
polyester and expanded polytetraﬂuoroethylene, are
routinely used to restore the blood ﬂow in patients with
various cardiovascular disorders. They still have many
disadvantages, such as thrombogenicity, intimal hyperpla-
sia, stenosis and occlusion (especially in the small caliber
grafts), susceptibility to infections, formation of pseudoa-
neurysms, and lack of growth potential [3,11e13]. There-
fore, a completely bioabsorbable vascular patch, capable
of inducing the regeneration of a new vessel wall, may
overcome the limitations of the current artiﬁcial patches,
serving as architectural support for the development of the
neotissue. Tissue engineering is focusing on the develop-
ment of biomaterials capable of mimicking the biologic and
mechanical functions of the extracellular matrix (ECM). In
fact, it has been shown that tissue morphogenesis is
strongly inﬂuenced by interactions between cells and the
ECM [14e26].
The present study aimed to test a new material as a
bioabsorbable substitute for blood vessels in a pig model.
This material initially should behave like the common
vascular prosthesis and, at a later stage, once degraded and
reabsorbed by the host organism, should replace the graft in
a new blood vessel with anatomic and functional charac-
teristics similar to those of native vascular vessels.METHODS
The scaffold we tested was created in the Biocompatible Polymer
Laboratory of the Department of Science and Molecular and
Biomolecular Technology (STEMBIO) of the University of
Palermo. It consists of electrospun ﬁbers based on synthetic
polymers. Electrospinning is a technique that uses a high voltage
source for biasing a polymer solution or a polymer melt, which is
then accelerated toward an opposite polarity collector. Through
electrospinning, one can obtain the 3-dimensional scaffold
composed of micronanometer polymeric ﬁbers, interconnected to
form a microporous structure [27,28]. a,b-Poly(N-2-hydroxyethyl-
D,L)-aspartamide (PHEA) is the starting polymer; we used it for
the production of copolymers for our scaffold. PHEA is a
biocompatible synthetic polymer, soluble in water, with a similar
structure to human amino acids. The use of PHEA as carriers of
drugs and as a starting material for many other biomedical and
pharmaceutical applications has already been reported [29,30].
PHEA was linked with polylactic acid (PLA) and subsequently
electrospun in a mixture with polycaprolactone (PCL) [31,32].
Scaffolds obtained from the PHEA-PLA/PCL mixture had ﬁbers
with diameters from 500 nm to 1 mm, similar to the ECM. In fact,
the adhesion, proliferation and differentiation of cells are strongly
inﬂuenced by size, geometry, and density of the pores and the
surface properties [33e40]. From a study carried out previously by
our group, PHEA-PLA/PCL was found to be a biocompatible
material, elastic, and possessing great mechanical strength [41].The data obtained from in vivo experiments showed that the
material has good biocompatibility, evoking an inﬂammatory
response of modest degree, which has a prime role in the reab-
sorption of the material and processes of tissue regeneration.
Subsequently, the scaffold was made tubular in a structure with a
diameter of w5 mm and a length of a few centimeters. The
material was also bound to heparin by covalent bonding to reduce
the risk of thrombosis [42].
We performed an arteriovenous ﬁstula (AFV) between the
external left iliac artery and the external left iliac vein in a
4-month-old pig model weighing 40 kg. Our experiments were
conducted according to the provisions of Legislative Decree no 26
of March 4, 2014, implementing Directive 2010/63/EU on the
protection of animals used for scientiﬁc purposes, after regulatory
approval of the project by the Italian Ministry of Health.
All animal experiments were in compliance with the Animal
Research: Reporting of In Vivo Experiments guidelines and were
carried out in accordance with the EU Directive 2010/63/EU
guidelines for animal experiments, the National Institutes
of Health guide for the care and use of laboratory animals
(legislative decree no 26, March 4, 2014) and the Organismo
Preposto al Benessere Animale of the “A. Mirri” Zooprophylactic
Institute.
The anesthetic protocol included premedication (6.3 mg/kg
zolazepam tiletamine þ 2.3 mg/kg xylazine), induction (0.5 mg/kg
propofol), andmaintenance (isoﬂuraneþ pancuronium, 12:7 mg/kg).
After obtaining access to “J” in the left iliac fossa, we proceeded to the
isolation of the iliac vessels and packaging of secondary arteriovenous
ﬁstula between the left external iliac artery and the vein ipsilateral
homologous, with lateroterminal anastomosis on the arterial side and
terminolateral anastomosis on the venous side; this was carried out by
means of double hemicontinuous suture of 180 with the use of a
suture thread of a nonabsorbable Prolene type 8-0 (Fig 1). At the
moment of the arterial unclamping, we were able, macroscopically, to
appreciate a good pulse rate on the prosthetic surface. After surgery,
the animal was subjected to a liquid diet for the ﬁrst 24 hours and
antibiotic treatment with the use of oxytetracycline (20 mg/kg/d for
3 days). The ﬂow within the AFV was assessed by means of Doppler
ultrasound examination with the use of a microconvex probe of 4e7.5
MHz. The study of the ﬂow was performed by means of Doppler
ultrasound every week. In the 1st 2 weeks, the Doppler checks
revealed the patency of our AFV (Fig 2). After 1 month, seeing the
Doppler scaffold thrombosis responses, we proceeded to en bloc
scaffold removal for histopathologic examination. The histologic
sections of the surgical specimen were analyzed, after ﬁxing in a 10%
formalin solution, with the use of hematoxylin-eosin staining.RESULTS
The bioresorbable tubular prosthesis proved to be easy to
handle and resistant to traction during the anastomoses.
The anastomosis proved to be leak proof, but subject to an
arterial pressure regime, as evidenced by the absence of
signs of intraoperative bleeding and early complications.
The scaffold developed by the STEMBIO laboratory also
seemed to accord with the suture needle passage, making it,
from a surgical point of view, particularly suited to clinical
applications. After this procedure, the scaffold remained
perfectly intact and impermeable to blood serum. The
scaffold showed great ﬂexibility, allowing it to pulsate in the
same manner as the adjacent arteries. Doppler examination
Fig 1. Bridge ﬁstula (s) between the left external iliac artery (a) and the ipsilateral homologous vein (v).
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the anastomosis, with a typically turbulent ﬂow (Fig 2).
Subsequent ultrasound evaluations revealed the patency of
the graft in the 1st 2 weeks and a thrombosis during the
Doppler control in the 3rd week.
Histologic examination showed a chronic granulomatous
“foreign body” inﬂammation with giant cells; this was
associated with a ﬁbrotic stromal reaction and multiple
small newly formed vessels. It was possible to still see the
presence of as yet unabsorbed material in the context of
granulomatous inﬂammation (Fig 3).Fig 2. Doppler ultrasound performed immediately after surgery,
showing the patency of the anastomosis, with a typically turbu-
lent ﬂow.DISCUSSION
The goal of tissue engineering is to obtain a biofunctional
and bioabsorbable scaffold, capable of fostering the regen-
eration of native tissue [43,44]. The possibility of producing
bioengineered vessels is the subject of several experimental
studies [45e66]; however, the material to be proposed as a
“scaffold ideal” has not yet been found [35e40,67e80]. The
scaffold created in the STEMBIO laboratories proved to be
biocompatible, as evidenced by our preliminary studies in
the mouse model and as conﬁrmed by the present experi-
ment with the use of the pig model. Our scaffold differs
from others used so far, because it seems to present the
structural characteristics that make it suitable for theFig 3. Chronic granulomatous “foreign body” inﬂammation with
giant cells, associated with a ﬁbrotic stromal reaction and multi-
ple small newly formed vessels.
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affected by the early hydrolysis phenomena which too
quickly degrade the other materials proposed so far. The
histologic results highlighted how the time required for the
degradation of our scaffold is >1 month. However, we were
able to observe the start of a regeneration process, as
evidenced by the presence of neovascularization with the
formation of an intricate vascular network associated with
characteristic cellular elements of chronic inﬂammation.
The electrospinning of PHEA-PLA in a mixture with PCL
resulted in a scaffold with excellent elasticity, probably
related to the regularity and dimensional uniformity of the
ﬁbers and the absence of a merger between them; these
morphologic characteristics are similar to those of the
native ECM. In addition, our vascular substitute showed
good mechanical properties, allowing easy handling during
the experiments conducted. After the AVF had been
created, arterial unclamping showed that the graft pre-
sented good compliance, responding to changes in blood
ﬂow and arterial pulse waves. The tensile properties and the
microporous structure are responsible for 2 other funda-
mental results of our research: the complete absence of
bleeding or serous leakage through the walls, and excellent
resistance to the needle suture passage, with a consequent
perfect seal of the anastomosis. The ultrastructure of the
scaffold, with an intricate plot of nanoﬁlaments distributed
over a thickness of w0.5 mm, enables the cells to colonize
the scaffold and, at the same time, prevents ﬂuid from
exuding from the surface. It is these same characteristics
that guarantee that this tissue remains intact during the
needle passage from the suture, because the ﬁbers are
spread apart and are not in any way damaged or severed by
the mechanical puncture. This resistance to tension gua-
rantees the perfect seal of the anastomosis, avoiding blood
loss at the point of suture. This characteristic resistance to
puncture may, prospectively, allow the use of such devices
for vascular access use, and, in particular, for the perform-
ing bridge ﬁstulas.
Polymer thrombogenicity was partially resolved by func-
tionalizing it with heparin molecules covalently bonded to
the nanostructure of the scaffold. Although the scaffold was
pervious only for a month, we had no evidence of early
thrombosis phenomena, despite the complete absence of
anticoagulant therapy. Heparin also had an important role
in guiding vascular endothelialization and by stimulating
numerous growth factors [42,81]. This would allow the
circulating stem cells to engraft to the implanted tissue and
promote the regeneration of a fabric (regarding mechanical
and biologic characteristics) similar to that of the host
organism. Three weeks after implantation, the graft showed
thrombosis phenomena; we think that one of the major
causes of thrombosis may have been an inappropriate
postoperative anticoagulant regimen. Probably, the absence
of ﬂow within the vascular graft did not allow effective
colonization, particularly in its central portion, an event that
contributed to only partial resorption of the material,
especially in the part farthest from the anastomosis area.CONCLUSION
The “ideal scaffold” boasts certain fundamental properties:
It must be made from biocompatible material, having a
degradation rate that corresponds to the production of new
ECM by the host; and it must possess the ability to interact
with host cells, mechanical properties, and ultrastructural
characteristics that match the target anatomic site.
The biocompatibility of PHEA-PLA/PCL and its physical
properties make it suitable in the replacement of vessels.
The main disadvantage is that its thrombogenicity is only
partially solved by adding heparin to the scaffold. To resolve
this issue and obtain a new vessel from a synthetic substi-
tute, we will need to conduct further studies in which indi-
vidualized anticoagulation treatments will be used; these
will be associated with the use of PHEA-PLA/PCL scaffolds
that could be further functionalized with growth factors to
modulate the inﬂammatory response and coagulation.
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